The PI3K/mTOR pathway Is targeted by rare germline variants in patients with both melanoma and renal cell carcinoma - CEA - Commissariat à l’énergie atomique et aux énergies alternatives Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2021

The PI3K/mTOR pathway Is targeted by rare germline variants in patients with both melanoma and renal cell carcinoma

Résumé

Background: Malignant melanoma and RCC have different embryonic origins, no common lifestyle risk factors but intriguingly share biological properties such as immune regulation and radioresistance. An excess risk of malignant melanoma is observed in RCC patients and vice versa. This bidirectional association is poorly understood, and hypothetic genetic co-susceptibility remains largely unexplored. Results: We hereby provide a clinical and genetic description of a series of 125 cases affected by both malignant melanoma and RCC. Clinical germline mutation testing identified a pathogenic variant in a melanoma and/or RCC predisposing gene in 17/125 cases (13.6%). This included mutually exclusive variants in MITF (p.E318K locus, N = 9 cases), BAP1 (N = 3), CDKN2A (N = 2), FLCN (N = 2), and PTEN (N = 1). A subset of 46 early-onset cases, without underlying germline variation, was whole-exome sequenced. In this series, thirteen genes were significantly enriched in mostly exclusive rare variants predicted to be deleterious, compared to 19,751 controls of similar ancestry. The observed variation mainly consisted of novel or low-frequency variants (<0.01%) within genes displaying strong evolutionary mutational constraints along the PI3K/mTOR pathway, including PIK3CD, NFRKB, EP300, MTOR, and related epigenetic modifier SETD2. The screening of independently processed germline exomes from The Cancer Genome Atlas confirmed an association with melanoma and RCC but not with cancers of established differing etiology such as lung cancers. Conclusions: Our study highlights that an exome-wide case-control enrichment approach may better characterize the rare variant-based missing heritability of multiple primary cancers. In our series, the co-occurrence of malignant melanoma and RCC was associated with germline variation in the PI3K/mTOR signaling cascade, with potential relevance for early diagnostic and clinical management.
Fichier principal
Vignette du fichier
cancers-13-02243.pdf (863.74 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

cea-04359980 , version 1 (21-12-2023)

Identifiants

Citer

Jean-Noël Hubert, Voreak Suybeng, Maxime Vallee, Tiffany M. Delhomme, Eve Maubec, et al.. The PI3K/mTOR pathway Is targeted by rare germline variants in patients with both melanoma and renal cell carcinoma. Cancers, 2021, 13 (9), pp.2243. ⟨10.3390/cancers13092243⟩. ⟨cea-04359980⟩
16 Consultations
24 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More